Results 121 to 130 of about 178,517 (322)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Bone Reports, 2019
Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation.
Yuko Ariza, Masayuki Murata, Yoshiko Ueda, Toshio Yoshizawa   +3 more
doaj  

Ibrutinib and Neurolisteriosis: Simple Coincidence?

Annals of Internal Medicine: Clinical Cases
Listeria monocytogenes is an opportunistic food-borne pathogen that can cross the blood–brain barrier and infect the central nervous system, causing potentially life-threatening neurolisteriosis, including brain abscess.
Paul Dalmas, Coline Mortier, Margaux Froidefond, Barbara Doudier, Pierre Dudouet, Aude Collignon, Mikael Ebbo, Jean-Christophe Lagier, Nadim Cassir   +8 more
doaj   +1 more source

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

Pharmacology Research & Perspectives, 2020
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders.
Krishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, Ankit Patel, Kinjal Thakkar, Dinesh Patel, Manoranjan Sharma, Jaideep Singh, Jogeswar Mohapatra, Abhijit Chatterjee, Dipam Patel, Rajesh Bahekar, Rajiv Sharma, Lakshmikant Gupta, Nirmal Patel, Poonam Giri, Nuggehally R. Srinivas, Mukul Jain, Debdutta Bandyopadhyay, Pankaj R. Patel, Ranjit C. Desai   +20 more
doaj   +1 more source

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

The Journal of Pathology, EarlyView.
Abstract In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Timár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics, Miklós Egyed, Zsuzsa Molnár, János Rottek, András Masszi, Péter Tamáska, Róbert Szász, Árpád Illés, Donát Alpár, Ferenc Magyari, Csaba Bödör   +19 more
wiley   +1 more source

Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3-kinase and Rho-family GTPases [PDF]

, 2000
Beston F. Nore, Leonardo Vargas, Abdalla J. Mohamed, Lars J. Brandén, Carl‐Magnus Bäckesjö, Tahmina Islam, Pekka T. Mattsson, Kjell Hultenby, Birger Christensson, Smith Rjh   +9 more
openalex   +2 more sources

PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.

ACS Chemical Biology, 2019
The impact of covalent binding on PROTAC-mediated degradation of BTK was investigated through the preparation of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib.
Christopher Tinworth, Hannah Lithgow, Lars Dittus, Zuni I. Bassi, S. E. Hughes, M. Muelbaier, H. Dai, I. E. Smith, W. Kerr, G. Burley, M. Bantscheff, J. Harling   +11 more
semanticscholar   +1 more source

Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Patients with ataxia–telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B‐cell lymphoma ...
Samanta Catueno, Ramya Ramakrishnan, Sarah Elitzur, Miriam B. Garcia, David McCall, Cesar Nunez, Michael Roth, Alessandra Ferrajoli, Branko Cuglievan, Amber Gibson   +9 more
wiley   +1 more source

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis

Drug Design, Development and Therapy, 2022
Edgar Carnero Contentti,1 Jorge Correale2,3 1Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina; 2Department of Neurology, Fleni, Buenos Aires, Argentina; 3Universidad de Buenos Aires-CONICET, Instituto de ...
Carnero Contentti E, Correale J
doaj  

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).

Journal of Medicinal Chemistry, 2019
Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.
S. H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, D. Batt, Ling Li, M. Pattoli, S. Skala, Lihong Cheng, M. Obermeier, Robin Moore, Zheng Yang, R. Vickery, P. Elzinga, Lorell N. Discenza, C. D’arienzo, Kathleen M. Gillooly, T. Taylor, C. Pulicicchio, Yifan Zhang, Elizabeth M. Heimrich, K. McIntyre, Q. Ruan, R. Westhouse, I. Catlett, Naiyu Zheng, C. Chaudhry, Jun Dai, Michael A. Galella, A. Tebben, M. Pokross, Jianqing Li, R. Zhao, Daniel J. Smith, R. Rampulla, A. Allentoff, M. Wallace, A. Mathur, L. Salter-Cid, J. Macor, P. Carter, A. Fura, J. Burke, J. Tino   +42 more
semanticscholar   +1 more source

Micro‐ and nanomotors in biomedical applications

Responsive Materials, EarlyView.
Micro‐ and nanomotors (MNMs), as autonomous devices converting chemical or external energy into mechanical propulsion, have emerged as transformative drug delivery platforms in biomedicine. This review systematically outlines the design principles governing MNMs' propulsion and operation, highlights the applications of MNMs in disease treatment, and ...
Xiangyu Meng, Yuqi Tang, Quan Li
wiley   +1 more source